Felipe Dominguez Machado

Felipe Dominguez Machado

Auto-generated profile, based on publicly available information

Felipe Dominguez Machado

Programa de Pós-Graduação em Ciências Pneumológicas, Universidade Federal do Rio Grande do Sul, Porto Alegre (RS), Brasil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
PDF file
CACamila Anton
Camila Anton
FMFelipe Dominguez Machado
Felipe Dominguez Machado
JRJorge Mario Ahumada Ramirez
Jorge Mario Ahumada Ramirez
RBRafaela Manzoni Bernardi
Rafaela Manzoni Bernardi
PPPenélope Esther Palominos
Penélope Esther Palominos
DSDenise Rossato Silva
Denise Rossato Silva
Most people infected by Mycobacterium tuberculosis (Mtb) do not have any signs or disease symptoms, a condition known as latent tuberculosis infection (LTBI). The introduction of biological agents, mainly tumor necrosis factor (TNF) inhibitors, for the treatment of immune-mediated diseases such as Rheumatoid Arthritis (RA) and other rheumatic diseases, increased the risk of reactivation of LTBI, leading to development of active TB. Thus, this review will approach the aspects related to LTBI in patients with rheumatologic diseases, especially those using iTNF drugs. For this purpose it will be considered the definition and prevalence of LTBI, mechanisms associated with diseases and medications in use, criteria for screening, diagnosis and treatment. Considering that reactivation of LTBI accounts for a large proportion of the incidence of active TB, adequate diagnosis and treatment are crucial, especially in high-risk groups such as patients with rheumatologic diseases.

7 October 2022 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
CLCarolina Xavier Lemos
Carolina Xavier Lemos
CACamila Anton
Camila Anton
FMFelipe Dominguez Machado
Felipe Dominguez Machado
RBRafaela Manzoni Bernardi
Rafaela Manzoni Bernardi
AFAlana Ambos Freitas
Alana Ambos Freitas
DSDenise Rossato Silva
Denise Rossato Silva
OBJECTIVES: In tuberculosis treatment, corticosteroids are used as adjuvants, especially in meningeal/pericardial tuberculosis. In other forms of the disease, especially in severe tuberculosis requiring mechanical ventilation, its use is controversial. The aim of the present study is to assess whether the use of corticosteroids in the treatment of pulmonary tuberculosis patients in mechanical ventilation is associated with in-hospital mortality.METHODS: This is a retrospective cohort study. Tuberculosis patients >18 years requiring mechanical ventilation, admitted to the emergency department or intensive care unit, were included. Data on corticosteroid use and mortality were collected.RESULTS: In total, 467 patients were included in the analysis; 399 used corticosteroids and 68 were noncorticosteroid users. The mortality rate was higher among corticosteroid users (59.9%) than in noncorticosteroid users (41.2%) (p=0.010). The total dose of corticosteroid in prednisone equivalents was not different between survivors and nonsurvivors (median [interquartile range]: 80 mg [5-56.6 mg] vs. 80 mg [50-135 mg]; p=0.881).CONCLUSIONS: Tuberculosis patients in mechanical ventilation who used corticosteroids had a higher mortality rate than those who did not use corticosteroids. The role of corticosteroids in pulmonary tuberculosis, especially in critically ill patients, remains unclear and needs further evaluation in prospective studies.